drugset / Trial / NCT06613425

Clinical Study of Combined Platelet Transfusion

NCT06613425 ↗

Phase 4 Recruiting 86 enrolled The General Hospital of Western Theater Command
NaSingle-groupOpen-labelTreatment

Summary

Platelet transfusion is an irreplaceable and important treatment method for clinical prevention and treatment of thrombocytopenia or platelet dysfunction. Due to various factors, it is difficult to achieve platelet ABO complete homotypic transfusion in clinical practice. When ABO-compatible platelets cannot be obtained, plasma-reduced platelets, platelets with low anti-A or anti-B titers are often used in clinical practice to reduce the risk of ABO-incompatible platelet-compatible transfusion reactions. The combined platelets prepared in this study can achieve ABO primary and secondary side compatible infusion.

Timeline

Start
2024-08-01
Primary completion
2025-07-29
Completion
2025-10-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Combined platelets Unknown 2.5e+11 cells —

Indications